Friday, 21 Jul 2017

You are here

Lymphopenia and Steroids Increase the Risk of Pneumocystis Jiroveci in Systemic Rheumatic Diseases

It is well-known that patients with systemic autoimmune diseases are at risk for Pneumocystis jirovecii pneumonia (PJP) and although infrequent, it carries a high mortality. A new study shows lymphopenia and steroid use increases the risk of PJP.

Prior to 1990 reports were rare, however increasing use of immunosuppression, particularly in combinations, improved diagnostic techniques and awareness of the disease have led to improved documentation.

Unlike in HIV where CD4 counts guide when to initiate PJP prophylaxis, there exists no biomarker in the rheumatology world though there has been a focus on the negative association between lymphocyte counts with PCP occurrence in immunocompromised hosts.  

In a recent edition of Seminars in Arthritis and Rheumatism, Tadros et al. presented the results of a case-control study that examined the differences in characteristics and peripheral blood parameters between patients with systemic rheumatic disease who did or did not develop PJP. The authors collected data between 2002 and 2013 from a single center in Melbourne, Australia to match 11 patients identified as having a systemic rheumatologic disease and PJP in a 1:4 ratio with matched controls.

After adjustments for glucocorticoid exposure and CRP, they found that lymphocyte count on admission (0.4 vs. 1.3; p=0.04) and nadir (0.2 vs. 0.8x109/L; p=0.05) were significantly lower in patients with PJP compared to controls.

We know that glucocorticoids are also a risk factor for PJP (and can cause lymphopenia, at least transiently), but this study is the first to show that lymphopenia is a risk factor independent of GC use.

While no consensus guidelines exist, monitoring lymphocyte counts may assist us in deciding when to initiate PJP prophylaxis; although it is unclear what cutoff values should be used.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Inflammatory and Autoimmune Diseases are Not Rare in HIV Patients

HIV infection and AIDs has been associated with numerous complications, presumeably resulting from impaired immunity from infection.  Sporadic cases and small cohorts of patients with rheumatic and autoimmune syndromes have been described but epidemiology data on the prevalence is scarce.

Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too

A population-based claim study from Sweden has shown that lupus and pre-lupus patients are at risk for adverse maternal and fetal outcomes.   

Cumulative Genetic Hit Hypothesis for Lupus

A recent report in Nature Communications has studied multiple nationalities has shown a "disentangled complex HLA multigenic effect" underlying the genetic basis of systemic lupus erythematosus (SLE).  (Citation source: http://buff.ly/2u623Ht)

Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus

Systemic lupus erythematosus (SLE) is associated with an increased risk of cardiovascular disease (CVD). The cardioprotective benefits of aspirin (ASA) are well known and the ancillary CV and diabetogenic effects of hydroxychloroquine (HCQ) have also been shown.  A current study in the Journal of Rheumatology has shown that thromboprophylaxis with low-dose ASA and HCQ) yields CVD benefits in SLE.

 

Alveolar Hemorrhage in Lupus Needs Prompt Evaluation

Acute diffuse lung infiltration in patients with systemic lupus erythematosus (SLE) requires prompt evaluation for diffuse alveolar hemorrhage (DAH) when patients have low levels of hemoglobin and complement compound C4 and symptoms of hypoxia. The development of DAH was significantly associated with the presence of these features, South Korean researchers have found.